Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)

As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date rally and a resilient "soft landing" for the U.S. economy, a stark divergence has emerged

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three quarters of the year, the rare-disease specialist has encountered a late-year slump, retreating from its 52-week

The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Let's have a look at the gap up and gap down stocks in today's session.

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

They could ride the wave of the hottest therapeutic area in the industry.

Rhythm Pharmaceuticals Q2 2025 results show revenue beat but EPS miss, causing a 5.7% pre-market drop. Regulatory progress for setmelanotide remains on track.

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.